(NewsDirect)
EmyriaLtd (ASX:EMD) MD Michael Winlo tells Proactive the company hasrecruited the first patient for its Phase 2B MDMA-assisted therapytrial for post-traumatic stress disorder (PTSD).
The EMDMA-001 trial hasbeen designed to assess the safety, efficacy and cost-effectiveness ofMDMA-assisted therapy for PTSD.
It aims to generate vital data that will strengthenEmyria's position as a leader in providing psychedelic-assistedtherapy within a comprehensive multidisciplinary clinicalservice.
The newscomes soon after Emyria announced it was acquiring the Pax Centre,Australia’s leading multidisciplinary psychological trauma careservice.
It bringsa top-tier clinical service into the EMD fold, expanding itscapabilities as it develops therapies to meet a burgeoningmarket.
A report from InsightAceAnalytics expects the total addressable market for psychedelicassisted therapies to reach US$8.31 billion by 2028.
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
Jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.